Buy Mosapride Citrate Dihydrate Raw API Gastroprokinetic Agent Drug For Gastritis Online CAS 112885-42-4
Mosapride citrate dihydrate Specification
Product Name: Mosapride citrate dihydrate
CAS: 112885-42-4
Natural/Synthetic: Synthetic
Level: Pharmaceutical grade
Content: 99%
Appearance: white powder
Packing: 1kg/aluminum foil bag
Category: Pharmaceutical Raw Materials
Field: digestive tract prokinetic agent
Down products: mosapride citrate tablets, dispersible tablets, mosapride citrate capsules
Use: For functional dyspepsia with heartburn, belching, nausea, vomiting, early satiety, upper abdominal distension and other gastrointestinal symptoms; can also be used for gastroesophageal reflux disease, diabetic gastroparesis and some patients with gastrectomy Gastric dysfunction.
What is Mosapride?
Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome.
It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).
Mosapride citrate dihydrate certificate of analysis
| Product name |
Mosapride Citrate Dihydrate |
| CAS No. |
112885-42-4 |
Outer Packing |
1kg/foil bag |
| Production date |
2018-2-21 |
Shelf life |
2 years |
| Standard adopted |
Enterprise standard |
| Items of analysis |
Specification |
Results |
| Characters |
White or yellowish crystalline powder odorless |
Conforms |
| Identification |
|
|
| Chemical feaction |
Show a positive reaction on Citrate The retention times of the major peaks are |
Conforms |
| HPLC |
Consistent with the standard preparation as obtained in the Assay |
Conforms |
| IR |
The infrared absorption spectrum is consistent with the spectrum of Mosapride Citrate referance |
Conforms |
| Water |
5.0~6.5% |
5.7% |
| Fluorine |
2.6~3.2% |
2.8% |
| Chloride |
Not more than 0.5% |
Conforms |
| Sulfate |
Not more than 0.08% |
Conforms |
| Related Substance |
|
|
| Any individual impurity |
Not more than 0.5% |
0.04% |
| The sum of all impurities |
Not more than 1.0% |
0.13% |
| Residual solvents |
|
|
| Methanol |
Not more than 0.3% |
Not detected |
| Ethanol |
Not more than 0.5% |
0.04% |
| Dichloromethane |
Not more than 0.06% |
Not detected |
| Chloroform |
Not more than 0.006% |
Not detected |
| Toluene |
Not more than 0.089% |
Conforms |
| Residual on ignition |
Not more than 0.1% |
Conforms |
| Heavy Metals |
Not more than 20ppm |
Conforms |
| Assay |
Not less than 98.5% of |
99.8% |
| Conclusion |
Qualified |
Mosapride Side Effects
Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhea and sometimes constipation.
Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans.
Due to the pharmacokinetics of mosapride, it would take 1,000–3,000 times the therapeutic dose to elicit cardiovascular effects.
